

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

July 2013

Vol. 41, No. 7

## CONTENTS

### SHORT COMMUNICATIONS

Ion Mobility Spectrometry–Mass Spectrometry Analysis for the Site of Aromatic Hydroxylation. *Atsushi Shimizu and Masato Chiba* . . . . . **1295**

Acrolein, an  $\alpha,\beta$ -Unsaturated Aldehyde, Irreversibly Inhibits the Acetylation of Aromatic Amine Xenobiotics by Human Arylamine *N*-Acetyltransferase 1. *Linh C. Bui, Amine Manaa, Ximing Xu, Romain Duval, Florent Busi, Jean-Marie Dupret, Fernando Rodrigues-Lima, and Julien Dairou* . . . . . **1300**

### ARTICLES

Stereoselective Glucuronidation of Ornidazole in Humans: Predominant Contribution of UDP-Glucuronosyltransferases 1A9 and 2B7. *Jiangbo Du, Tiangeng You, Xiaoyan Chen, and Dafang Zhong* . . . . . **1306**

□ Mechanistic Pharmacokinetic-Pharmacodynamic Modeling of BACE1 Inhibition in Monkeys: Development of a Predictive Model for Amyloid Precursor Protein Processing. *Xingrong Liu, Harvey Wong, Kimberly Searce-Levie, Ryan J. Watts, Melis Coraggio, Young G. Shin, Kun Peng, Kristin R. Wildsmith, Jasvinder K. Atwal, Jason Mango, Stephen P. Schauer, Kelly Regal, Kevin W. Hunt, Allen A. Thomas, Michael Siu, Joseph Lyssikatos, Gauri Deshmukh, and Cornelis E. C. A. Hop* . . . . . **1319**

Optimization of Drug-Drug Interaction Study Design: Comparison of Minimal Physiologically Based Pharmacokinetic Models on Prediction of CYP3A Inhibition by Ketoconazole. *Bing Han, Jialin Mao, Jenny Y. Chien, and Stephen D. Hall* . . . . . **1329**

In Vitro and In Vivo Human Metabolism of Degarelix, a Gonadotropin-Releasing Hormone Receptor Blocker. *Anders Sonesson and Birgitte Buur Rasmussen* . . . . . **1339**

□ Variability in P-Glycoprotein Inhibitory Potency ( $IC_{50}$ ) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria. *Joe Bentz, Michael P. O'Connor, Dallas Bednarczyk, JoAnn Coleman, Caroline Lee, Johan Palm, Y. Anne Pak, Elke S. Perloff, Eric Reyner, Praveen Balimane, Marie Brännström, Xiaoyan Chu, Christoph Funk, Ailan Guo, Imad Hanna, Krisztina Herédi-Szabó, Kate Hillgren, Libin Li, Evelyn Hollnack-Pusch, Masoud Jamei, Xuena Lin, Andrew K. Mason, Sibylle Neuhoff, Aarti Patel, Lalitha Podila, Emile Plise, Ganesh Rajaraman, Laurent Salphati, Eric Sands, Mitchell E. Taub, Jan-Shiang Taur, Dietmar Weitz, Heleen M. Wortelboer, Cindy Q. Xia, Guangqing Xiao, Jocelyn Yabut, Tetsuo Yamagata, Lei Zhang, and Harma Ellens* . . . . . **1347**

□ Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. *Harma Ellens, Shibing Deng, JoAnn Coleman, Joe Bentz, Mitchell E. Taub, Isabelle Ragueneau-Majlessi, Sophie P. Chung, Krisztina Herédi-Szabó, Sibylle Neuhoff, Johan Palm, Praveen Balimane, Lei Zhang, Masoud Jamei, Imad Hanna, Michael O'Connor, Dallas Bednarczyk, Malin Forsgard, Xiaoyan Chu, Christoph Funk, Ailan Guo, Kathleen M. Hillgren, LiBin Li, Anne Y. Pak, Elke S. Perloff, Ganesh Rajaraman, Laurent Salphati, Jan-Shiang Taur, Dietmar Weitz, Heleen M. Wortelboer, Cindy Q. Xia, Guangqing Xiao, Tetsuo Yamagata, and Caroline A. Lee* . . . . . **1367**

□ Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-*b*]thiazole-Based Inverse Agonists of the Ghrelin Receptor. *Amit S. Kalgutkar, Tim F. Ryder, Gregory S. Walker, Suvi T. M. Orr, Shawn Cabral, Theunis C. Goosen, Kimberly Lapham, and Heather Eng* . . . . . **1375**

Human UDP-Glucuronosyltransferase (UGT) 2B10 in Drug *N*-Glucuronidation: Substrate Screening and Comparison with UGT1A3 and UGT1A4. *Yukiko Kato, Takeshi Izukawa, Shingo Oda, Tatsuki Fukami, Moshe Finel, Tsuyoshi Yokoi, and Miki Nakajima* . . . . . **1389**

Continued on next page

- Effects of Traditional Chinese Medicine *Wuzhi* Capsule on Pharmacokinetics of Tacrolimus in Rats. *Hua Wei, Xia Tao, Peng Di, Yingbo Yang, Jingxian Li, Xiaofeng Qian, Jin Feng, and Wansheng Chen*. . . **1398**
- ▣ The Effect of Breast Cancer Resistance Protein, Multidrug Resistant Protein 1, and Organic Anion-Transporting Polypeptide 1B3 on the Antitumor Efficacy of the Lipophilic Camptothecin 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin (AR-67) In Vitro. *Eleftheria Tsakalozou, Eyob D. Adane, Kuei-Ling Kuo, Abigail Daily, Jeffrey A. Moscow, and Markos Leggas*. . . . . **1404**
- ▣ Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions. *Yoshiyuki Shirasaka, Jennifer E. Sager, Justin D. Lutz, Connie Davis, and Nina Isoherranen*. . . . . **1414**
- Characterization of Recombinantly Expressed Rat and Monkey Intestinal Alkaline Phosphatases: In Vitro Studies and In Vivo Correlations. *Murali Subramanian, Sundeep Paruchury, Shashyendra Singh Gautam, Sheelendra Pratap Singh, Rambabu Arla, Sonia Pahwa, Snehasis Jana, Prasannakumar Katnapally, Vadari Yoganand, Basanth Lakshmaiah, Debarati Mazumder Tagore, Kaushik Ghosh, Punit Marathe, and Sandhya Mandlekar*. . . **1425**
- ▣ Dynamic Modeling of Cytochrome P450 Inhibition In Vitro: Impact of Inhibitor Depletion on IC<sub>50</sub> Shift. *Loren M. Berry, Zhiyang Zhao, and Min-Hwa Jasmine Lin*. . . . . **1433**
- Integrated Approach of In Vivo and In Vitro Evaluation of the Involvement of Hepatic Uptake Organic Anion Transporters in the Drug Disposition in Rats Using Rifampicin as an Inhibitor. *Tomoki Imaoka, Tsuyoshi Mikkaichi, Koji Abe, Masakazu Hirouchi, Noriko Okudaira, and Takashi Izumi*. . . . . **1442**
- Aspirin Hydrolysis in Human and Experimental Animal Plasma and the Effect of Metal Cations on Hydrolase Activities. *Fatma Goksin Bahar and Teruko Imai*. . . . . **1450**
- ▣ Combinatorial Metabolism Notably Affects Human Systemic Exposure to Ginsenosides from Orally Administered Extract of *Panax notoginseng* Roots (Sanqi). *Zheyi Hu, Junling Yang, Chen Cheng, Yuhong Huang, Feifei Du, Fengqing Wang, Wei Niu, Fang Xu, Rongrong Jiang, Xiumei Gao, and Chuan Li*. . . . . **1457**

▣ Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* Predicted relative contribution of OMP and its metabolites to reversible ( $I/IC_{50}$ ) and irreversible ( $\lambda/k_{deg}$ ) CYP2C19 and CYP3A4 inhibition. The inhibition risk was predicted using unbound  $C_{max}$  values. See article by Shirasaka et al. on page 1414 of this issue.